This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Landmark Survey Of Prostate Biopsies Confirms Sampling Standard

TALLAHASSEE, Fla., Feb. 14, 2013  /PRNewswire/ -- Today, the findings of the largest reported study on prostate biopsies were released at the American Society of Clinical Oncology Genitourinary Cancers Symposium in Orlando. The research confirmed that cancer detection rates are enhanced when 10 to 12-specimens are obtained during the biopsy.

"The study, which included over 4.2 million specimens collected from nearly 440,000 biopsies, confirms that biopsy regimens with 10 to 12 specimen cores results in an increased detection of prostate cancer," said Carl A. Olsson, M.D., F.A.C.S., co-author of the study, Chief Medical Officer of Integrated Medical Professionals, PLLC and a pre-eminent thought leader in urologic oncology. "Increased cancer detection rate correlated significantly with increased number of specimens examined."

The study, Utilization and cancer detection by U.S. prostate biopsies (2005-2011), assessed positive biopsy rates and core sampling patterns in patients whose prostate biopsies were submitted to either a national reference laboratory (NRL) or laboratory integrated into a urology group practice (UPL).  The study analyzed the relationship between positive biopsy rates and number of specimen vials per biopsy. The vials per biopsy were calculated in aggregate and separately for each site of service.

Research found that from 2005-11, the average positive prostate biopsy rate of 40.3% was identical at both the NRL and UPL.  Furthermore, the sharpest increase in the number of specimen vials obtained per biopsy was noted between the period 2005-08, corresponding to the development of extended core sampling regimens.  The study showed that at present, there is no significant difference in number of specimen vials submitted per biopsy, regardless of site of service.   

"This data, which represents the work product of over 2,000 urologists, indicates that physicians modified their clinical patterns to reflect best practices as suggested by the peer-reviewed literature," continued Dr. Deepak A. Kapoor, principal author and President of the Large Urology Group Practice Association. "The fact that there was no difference in either positive biopsy rate or specimen vials submitted across sites of service definitively demonstrates that appropriate medical necessity, not physician ownership, determines utilization of services."

The American Association of Clinical Urologists (AACU), American Urological Association (AUA), and the Large Urology Group Practice Association (LUGPA) joined together in applauding the release of the findings and stand in support of sampling at least 10 to 12 cores to ensure highest amount of cancers are detected. The 10 to 12 sampling protocol is now a de facto national standard.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 1.64%
FB $117.43 -0.96%
GOOG $692.36 -0.84%
TSLA $232.32 -3.92%
YHOO $36.01 -1.42%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs